Cardiac Implants Companies | Market Research Future

Top Industry Leaders in the Cardiac Implants Market

*Disclaimer: List of key companies in no particular orderLatest cardiac implants Companies Update

Aug 2023: With a share of 57% in the fiercely competitive US tissue suture aortic valve replacement industry as of 2022, Edwards Lifesciences was the market leader. Aortic valves manufactured by Edwards Lifesciences include the Perimount, Magna, and Inspiris Resilia models. Abbott Laboratories is a well-known competitor in the tissue sAVR industry, but it only holds a 5% market share thanks to its two products, the Trifecta GT aortic valve and Biocor Stent Tissue. The Trifecta GT aortic valve will no longer be sold in the US tissue sAVR market, the manufacturer has revealed, because of increased structural valve degeneration. According to the relevant regulatory frameworks, Abbott is currently starting inventory-related activities for leftover Trifecta and Trifecta GT valves worldwide. Some of Abbott's initial shares will probably be transferred to Edwards Lifesciences because Abbott currently possesses just one product on the US tissue sAVR market.

July 2023: The annual sales and profit predictions for Edwards Lifesciences Corp were marginally increased, but slower-than-expected growth in revenue in the manufacturer of artificial heart valves caused its shares to decline 6% after the bell. However, heart surgeries have not returned as quickly as other procedures, affecting medical equipment producers counting on a robust rebound. Staffing shortages at American hospitals have improved, which has increased non-urgent treatments delayed by the epidemic. This is partially because some surgeries take longer to complete—four to six months from the initial diagnosis. During a conference call, the business stated that lower-than-expected growth in the market and competition trialing in the initial half of this year were still putting pressure on sales in Japan.

List of cardiac implants Key companies in the market